KI, OUH, Forskningsenhed for Dermatovenerologi og allergi (Odense)

Medicin og biovidenskab

1. Hypersensitivity 100%
2. Allergens 57%
3. Patch Tests 48%
4. Hereditary Angioedemas 48%
5. Psoriasis 45%
6. Skin 37%
7. Atopic Dermatitis 36%
8. Asthma 36%
9. Immunoglobulin E 34%
10. Contact Dermatitis 30%
11. Eczema 30%
12. Odorants 27%
13. Denmark 24%
14. Allergic Contact Dermatitis 24%
15. Therapeutics 23%
16. Dermatitis 23%
17. Anaphylaxis 23%
18. Food Hypersensitivity 22%
19. Dermatology 22%
20. Asteraceae 22%
21. Mastocytosis 22%
22. Angioedema 22%
23. Allergic Rhinitis 20%
24. Allergy and Immunology 20%
25. Child 19%
26. Guidelines 18%
27. Immunologic Desensitization 17%
28. Systematic Reviews 15%
29. Chronic Urticaria 15%
30. Rhinitis 15%
31. Sesquiterpenes 15%
32. Adrenal Cortex Hormones 15%
33. Lactones 15%
34. Multicenter Studies 14%
35. Cohort Studies 14%
36. Urticaria 14%
37. Quality of Life 14%
38. Systemic Mastocytosis 14%
39. Hand 13%
40. Safety 13%
41. Food 13%
42. Mutation 13%
43. Nickel 13%
44. Venoms 13%
45. Irritants 12%
46. Skin Tests 12%
47. Mast Cells 12%
48. Pharmaceutical Preparations 12%
49. 2-methyl-4-isothiazolin-3-one 12%
50. icatibant 12%
51. Basophils 11%
52. Hymenoptera 10%
53. Cosmetics 10%
54. Histamine Release 10%
55. Immunotherapy 10%
56. Tiotropium Bromide 10%
57. Pets 9%
58. Arachis 9%
59. Delivery of Health Care 9%
60. Parturition 9%
61. Placebos 9%
62. Deodorants 9%
63. Dermatologists 8%
64. Biological Products 8%
65. Chronic Obstructive Pulmonary Disease 8%
66. Angiotensin-Converting Enzyme Inhibitors 8%
67. Pollen 7%
68. hydroxyisohexyl 3-cyclohexene carboxaldehyde 7%
69. Perfume 7%
70. isoeugenol 7%
71. Cutaneous Lupus Erythematosus 7%
72. Ichthyosis 7%
73. Histamine Antagonists 7%
74. Peanut Hypersensitivity 7%
75. Multimorbidity 7%
76. 5-chloro-2-methyl-4-isothiazolin-3-one 7%
77. Edema 7%
78. Skin Diseases 7%
79. Population 7%
80. Occupational Dermatitis 7%
81. parthenolide 7%
82. Skin Neoplasms 7%
83. T-Lymphocytes 7%
84. Genes 7%
85. Technology 6%
86. Hereditary Angioedema Types I and II 6%
87. nickel sulfate 6%
88. Meta-Analysis 6%
89. Patient Compliance 6%
90. Biosimilar Pharmaceuticals 6%
91. Hair Dyes 6%
92. Chronic Disease 6%
93. Serum 6%
94. Complement C1 Inhibitor Protein 6%
95. Registries 6%
96. Neoplasms 6%
97. Healthy Aging 6%
98. Triticum 6%
99. secukinumab 6%
100. Coronavirus 6%